Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Antipsychotic drugs do not affect platelet 5-HT concentration in schizophrenic patients (CROSBI ID 187142)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Šagud, Marina ; Nikolac, Matea ; Mihaljević-Peleš, Alma ; Nedić, Gordana ; Vuksan Čusa, Bjanka ; Mustapić, Maja ; Marčinko, Darko ; Jakovljević, Miro ; Muck-Šeler, Dorotea ; Pivac, Nela Antipsychotic drugs do not affect platelet 5-HT concentration in schizophrenic patients // Translational Neuroscience, 3 (2012), 1; 56-60. doi: 10.2478/s13380-012-0001-5

Podaci o odgovornosti

Šagud, Marina ; Nikolac, Matea ; Mihaljević-Peleš, Alma ; Nedić, Gordana ; Vuksan Čusa, Bjanka ; Mustapić, Maja ; Marčinko, Darko ; Jakovljević, Miro ; Muck-Šeler, Dorotea ; Pivac, Nela

engleski

Antipsychotic drugs do not affect platelet 5-HT concentration in schizophrenic patients

Rationale: Although antipsychotic drugs are prescribed for the treatment of schizophrenia and psychotic disorders, some of these drugs are also reported to possess antidepressant properties. Therefore, they are more frequently used either as a monotherapy or as an addition to antidepressant medication treatment in depression. Objectives: The data on the effects of antipsychotic drugs on serotonin (5-hydroxytryptamine, 5-HT) transporter (5-HTT) in vivo when given to patients in therapeutic doses are still scarce. Methods: Patients with schizophrenia or schizoaffective disorders in both male and female patients, were treated with antipsychotic drugs: 25 patients received olanzapine (12.8 ± 2.8 mg/day), 14 patients were treated with typical antipsychotic, fluphenazine N=14 (10.5 ± 2.5 mg/day) and for comparison, 21 patients were treated with ziprasidone (109.0 ± 27.1 mg/day). Platelet 5-HT concentration was determined fluorimetrically and evaluated at baseline and after 28 days in 65 healthy control subjects and in 60 patients. Results: Platelet 5-HT concentration did not differ significantly [F(3, 246)=0.597 ; p=0.677] between medicationfree healthy control subjects sampled at baseline and after 28 days compared to schizophrenic patients sampled before and 28 days after antipsychotics. Tukey’s multiple comparison test revealed that treatment with fluphenazine (p=0.853), olanzapine (p=0.117), or ziprasidone (p=1.000) did not significantly alter platelet 5-HT concentration after 28 days of treatment compared to their baseline values, i.e. values before treatment. Conclusions: Although all antipsychotics used in the study possess some antidepressant effects that are assumed to be related to their serotonergic properties, and have been reported to have in vitro binding affinity for human 5-HTT, the present study failed to detect significant in vivo effects of typical (fluphenazine) or atypical (olanzapine, ziprasidone) antipsychotics on platelet 5-HT concentration in schizophrenic patients.

olanzapine ; fluphenazine ; ziprasidone ; platelet serotonin ; schizophrenia

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

3 (1)

2012.

56-60

objavljeno

2081-3856

2081-6936

10.2478/s13380-012-0001-5

Povezanost rada

Kliničke medicinske znanosti, Temeljne medicinske znanosti

Poveznice
Indeksiranost